Lung CME
CME Activities

Optimizing the Use of Targeted Therapies in First and Subsequent Lines of Treatment for ALK-Positive Non-Small Cell Lung Cancer CME Credits: 0.5
Although non-small cell lung cancer (NSCLC) is a lung cancer subtype that comprises up to 90% of patients diagnosed with cancer, it continues to be a leading cause of cancer death.
Faculty: Stefanie Houseknecht, PharmD, BCOP, and Kristen A. Marrone, MD Expires: 4/15/2020

Emerging Options for Treating Small Cell Lung Cancer: The Potential Role of Immune Checkpoint Inhibitors CME Credits: 0.5
Small cell lung cancer (SCLC) is an aggressive malignancy that grows and disseminates rapidly. Although patients with metastatic SCLC respond well to conventional cancer treatments like platinum-based chemotherapy and radiation, most patients relapse within 1 year and have few therapeutic options.
Faculty: David S. Ettinger, MD Expires: 5/31/2020

Immunotherapy for the Treatment of Non-Small Cell Lung Cancer CME Credits: 1
Lung cancer is the leading cause of cancer-related mortality in the world, and approximately 85% of all lung cancer patients are diagnosed with non-small cell lung cancer (NSCLC).
Faculty: Jarushka Naidoo and Beatriz Wills Expires: 5/31/2020

Improving Outcomes in Stage III NSCLC: The Emerging Role of Immunotherapy in Curbing Disease Progression CME Credits: 0.5
Lung cancer is the worldwide leading cause of cancer-related mortality. The vast majority of these cases (about 85%) are characterized as nonsmall-cell lung cancer (NSCLC).
Faculty: Kristen Ashley Marrone, MD Expires: 5/31/2020

Addressing Unmet Needs in Mesothelioma: Evaluating the Role of Angiokinase Inhibitors CME Credits: 0.5
Malignant pleural mesothelioma (MPM) is a relatively rare but serious malignancy that arises from the mesothelial surfaces of the pleural cavity. Most cases of MPM are associated with workplace exposure to high levels of asbestos, with the onset of cancer typically occurring 20 to 50 years after asbestos exposure.
Faculty: Patrick Forde, MBBCh Expires: 3/5/2019